Oncolytic Virus Delivery Modulated Immune Responses Toward Cancer Therapy: Challenges and Perspectives

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Oncolytic Virus Delivery Modulated Immune Responses Toward Cancer Therapy: Challenges and Perspectives Publisher Pubmed

Keshavarz M¹ ; Mohammad Miri S² ; Behboudi E³ ; Arjeini Y⁴ ; Dianatmoghadam H⁵ ; Ghaemi A²

Source: International Immunopharmacology Published:2022

Abstract

Oncolytic viruses (OVs) harness the hallmarks of tumor cells and cancer-related immune responses for the lysis of malignant cells, modulation of the tumor microenvironment, and exertion of vaccine-like activities. However, efficient clinical exploitation of these potent therapeutic modules requires their systematic administration, especially against metastatic and solid tumors. Therefore, developing methods for shielding a virus from the neutralizing environment of the bloodstream while departing toward tumor sites is a must. This paper reports the latest advancements in the employment of chemical and biological compounds aimed at safe and efficient delivery of OVs to target tissues or tumor deposits within the host. © 2022 Elsevier B.V.

Related Docs

View other Related Docs

1. Mesenchymal Stem Cell-Released Oncolytic Virus: An Innovative Strategy for Cancer Treatment, Cell Communication and Signaling (2023)

2. Oncolytic Newcastle Disease Virus Delivered by Mesenchymal Stem Cells-Engineered System Enhances the Therapeutic Effects Altering Tumor Microenvironment, Virology Journal (2020)

3. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)

Experts (# of related papers)

View all Related Experts

Hassan Dianat Moghadam (3)

Jaleh Varshosaz (2)

Other Related Docs

4. Multifunctional Plant Virus Nanoparticles in the Next Generation of Cancer Immunotherapies, Seminars in Cancer Biology (2022)

5. Oncolytic Virotherapy Improves Immunotherapies Targeting Cancer Stemness in Glioblastoma, Biochimica et Biophysica Acta - General Subjects (2024)

6. Genetic Advancements in Breast Cancer Treatment: A Review, Discover Oncology (2025)

7. Engineered Small Extracellular Vesicles As a Novel Platform to Suppress Human Oncovirus-Associated Cancers, Infectious Agents and Cancer (2023)

8. Targeting Immune Checkpoints: How to Use Natural Killer Cells for Fighting Against Solid Tumors, Cancer Communications (2023)

9. Advances in Bioengineered Car T/Nk Cell Therapy for Glioblastoma: Overcoming Immunosuppression and Nanotechnology-Based Strategies for Enhanced Car T/Nk Cell Therapy, Bioengineering and Translational Medicine (2025)

10. Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination With Checkpoint Inhibitors and Beyond, Current Drug Targets (2022)

11. An Update on Antiviral Antibody-Based Biopharmaceuticals, International Immunopharmacology (2020)

12. Immunologic Tumor Microenvironment Modulators for Turning Cold Tumors Hot, Cancer Communications (2024)

13. Polymeric Nanoparticles in Cancer Chemotherapy: A Narrative Review, Iranian Journal of Public Health (2022)

14. Pegylated Trimethylchitosan Emulsomes Conjugated to Octreotide for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma Cells of Hepg2, Journal of Liposome Research (2019)

15. Exploring Metal-Organic Frameworks in Gene Delivery: From Prostate to Lung Therapeutics, Applied Materials Today (2024)

16. Non-Viral Delivery Systems for Breast Cancer Gene Therapy, Current Gene Therapy (2017)

17. The Therapeutic Effect of Mscs and Their Extracellular Vesicles on Neuroblastoma, Progress in Biophysics and Molecular Biology (2024)

18. Preparation and Evaluation of Targeted Albumin Lipid Nanoparticles With Lactobionic Acid for Targeted Drug Delivery of Sorafenib in Hepatocellular Carcinoma, Journal of Drug Delivery Science and Technology (2022)

19. Nanomaterials and Nanotechnology-Associated Innovations Against Viral Infections With a Focus on Coronaviruses, Nanomaterials (2020)

20. Cytotoxic Effects of Chitosan/Retinoic Acid/Albumin Targeted Nanoparticles Loaded With Doxorubicin on Human Hepatoma Cells, Journal of Isfahan Medical School (2013)

Style	Citing Format
MLA	Keshavarz M, et al.. "Oncolytic Virus Delivery Modulated Immune Responses Toward Cancer Therapy: Challenges and Perspectives." International Immunopharmacology, vol. 108, no. , 2022, pp. -.
APA	Keshavarz M, Mohammad Miri S, Behboudi E, Arjeini Y, Dianatmoghadam H, Ghaemi A (2022). Oncolytic Virus Delivery Modulated Immune Responses Toward Cancer Therapy: Challenges and Perspectives. International Immunopharmacology, 108(), -.
Chicago	Keshavarz M, Mohammad Miri S, Behboudi E, Arjeini Y, Dianatmoghadam H, Ghaemi A. "Oncolytic Virus Delivery Modulated Immune Responses Toward Cancer Therapy: Challenges and Perspectives." International Immunopharmacology 108, no. (2022): -.
Harvard	Keshavarz M et al. (2022) 'Oncolytic Virus Delivery Modulated Immune Responses Toward Cancer Therapy: Challenges and Perspectives', International Immunopharmacology, 108(), pp. -.
Vancouver	Keshavarz M, Mohammad Miri S, Behboudi E, Arjeini Y, Dianatmoghadam H, Ghaemi A. Oncolytic Virus Delivery Modulated Immune Responses Toward Cancer Therapy: Challenges and Perspectives. International Immunopharmacology. 2022;108():-.
BibTex	@article{ author = {Keshavarz M and Mohammad Miri S and Behboudi E and Arjeini Y and Dianatmoghadam H and Ghaemi A}, title = {Oncolytic Virus Delivery Modulated Immune Responses Toward Cancer Therapy: Challenges and Perspectives}, journal = {International Immunopharmacology}, volume = {108}, number = {}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Keshavarz M AU - Mohammad Miri S AU - Behboudi E AU - Arjeini Y AU - Dianatmoghadam H AU - Ghaemi A TI - Oncolytic Virus Delivery Modulated Immune Responses Toward Cancer Therapy: Challenges and Perspectives JO - International Immunopharmacology VL - 108 IS - SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Abstract